Granizetron Kabi

Granizetron Kabi is a prescription‑only intravenous product that contains the active ingredient granisetron hydrochloride. It belongs to the 5‑HT3 receptor antagonist class and is marketed in the European Union. The formulation is used to help prevent nausea and vomiting associated with chemotherapy and surgery. As an antiemetic, Granizetron Kabi works by selectively blocking serotonin receptors in the central nervous system. It is administered by a healthcare professional under controlled conditions.

Granizetron Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Prevention of postoperative nausea and vomiting (PONV) following surgical procedures. - Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated. - Administration in settings where rapid onset of antiemetic effect is required, such as during infusion of highly emetogenic agents. - Adjunctive therapy for patients who have experienced breakthrough nausea despite other antiemetics. - Optional use in clinical trials evaluating antiemetic strategies.

Granizetron Kabi may cause side effects that are generally mild and transient, reflecting its pharmacologic action on serotonin receptors. Most patients experience only minor symptoms, while rare serious reactions require immediate medical attention.

Common: - Headache – mild to moderate intensity, often resolves without treatment. - Constipation – decreased bowel movements, may be managed with dietary measures. - Fatigue or drowsiness – feeling of tiredness or reduced alertness. - Transient dizziness – brief episodes of light‑headedness, usually self‑limiting.

Serious: - Severe allergic reaction – signs include rash, itching, swelling, or difficulty breathing (anaphylaxis). - Cardiac arrhythmia or QT interval prolongation – may present as palpitations or irregular heartbeat. - Persistent severe abdominal pain – could indicate intestinal obstruction or other serious condition.

When prescribing Granizetron Kabi, clinicians should consider several precautionary factors to ensure safe use. These considerations address patient history, concomitant conditions, and monitoring requirements.

- Assess for known hypersensitivity to granisetron or other 5‑HT3 antagonists before administration. - Use caution in patients with a history of cardiac conduction disorders or prolonged QT interval. - Evaluate renal and hepatic function, as severe impairment may affect drug clearance. - Monitor for signs of serotonin syndrome when combined with serotonergic agents. - Consider risk‑benefit assessment in pregnant or breastfeeding women; use only if clearly indicated.

Granizetron Kabi may interact with other medications; understanding these interactions helps minimize adverse effects. Some drug combinations should be avoided, while others require careful monitoring.

Avoid: - Concurrent use with other 5‑HT3 receptor antagonists, which can increase risk of cardiac toxicity. - Co‑administration with drugs known to markedly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution: - Serotonergic agents such as SSRIs, SNRIs, or tramadol, due to potential serotonin syndrome. - Anticholinergic medications, which may exacerbate constipation. - CYP3A4 inhibitors or inducers, as they can alter granisetron plasma levels. - Anesthetic agents used during surgery, requiring coordination with the anesthesia team.